1-3 of 3
Ana Batlle, MD
Close
Sort by
Journal Articles

Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry

Silvia Solorzano, Carmen Martinez-Chamorro, Carlos Panizo, Cristina Quero, Guillermo Deben, MD, Jose Paz, Ana Batlle, MD, Alfons Serrano, Zayda Muentes, Antonio Gutierrez, MD, PhD, Jose Francisco Tomas, MD
Journal: Blood
Blood (2013) 122 (21): 5094.
https://doi.org/10.1182/blood.V122.21.5094.5094
Published: 2013
Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Santiago Montes-Moreno, Ana Batlle, MD, Sonia Gonzalez de Villambrosia, MD, Beatriz Sanchez-Espiridión, PhD, Laura Cereceda, Eva González-Barca, Purroy Noelia, MD, Emilia Pardal, Elena Sebastian, Alejandro Martin, Carlos Grande, Francisco Mazorra, MD, Andrés Insunza, Antonio Rueda, MD, Marta Llanos, MD, Jose Gomez Codina, MD, Francisco Ramon Garcia Arroyo, MD, Dolores Caballero, MD, Eulogio Conde, Andrés Lopez, MD, Mariano Provencio, Miguel Piris, MD
Journal: Blood
Blood (2012) 120 (21): 2672.
https://doi.org/10.1182/blood.V120.21.2672.2672
Published: 2012
Journal Articles

Bcl-6 May Be a Survival Factor in Pre-B Cell Ph+ Blast Crisis Cell Lines.

Ana Batlle, MD, Eric W. Lam, PhD, Simon D. Wagner, PhD, FRCP
Journal: Blood
Blood (2007) 110 (11): 4536.
https://doi.org/10.1182/blood.V110.11.4536.4536
Published: 2007